Downloads

1. Wall Street Is Wary Of NAMs — And For Good Reason: The Evidentiary Shift 9/10/2026

   Part I of this series focuses on the evidentiary shift of how NAMs may change the architecture of evidence and how that transition unfolds.

2. Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up 9/9/2026

   SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.

3. Measuring Cellular Water Content As A New Tool For Organoid Characterization 9/9/2026

   A collaboration between MIT, KAIST, and Dana Farber Cancer Institute created a technology that, for the first time, quantifies water content in single organoids.

4. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

5. Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs 9/3/2026

   A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.

6. Bringing Novel ADC Formats Into The Clinic: AOC Process Development 9/3/2026

   Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.

7. Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies 9/3/2026

   Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

8. The Future Of Cancer Drug Discovery Is Targeted Immune Activation 9/2/2026

   Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.

9. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

   The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

10. Hybrid Pipette - Intuitive Manual Control, Rapid Electronic Aliquoting 9/1/2026

    Combine precise manual control with rapid repeat dispensing in one instrument. One-handed volume adjustment, intuitive controls, and flexible charging help streamline liquid handling.